NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER

NRG 肿瘤网络集团运营中心

• 批准号: 9128214
• 负责人: WALTER J. CURRAN
• 金额: $ 36.26万
• 依托单位: NRG ONCOLOGY FOUNDATION, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-17 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9128214
• 关键词: Adult; Biological Markers; Brain Neoplasms; Cancer Control; Cancer Control Research; Cancer Survivorship; Caring; Clinical Research; Clinical Trials; Colorectal Cancer; Decision Making; Development; Developmental Therapeutics Program; Diagnostic; Diagnostic Neoplasm Staging; Disease; Endometrial Carcinoma; Enrollment; Gender; Gynecologic Oncology Group; Head and Neck Cancer; Image; Information Technology; Investigational Therapies; Knowledge; Leadership; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of lung; Malignant neoplasm of ovary; Malignant neoplasm of prostate; Medical Technology; Mission; Modeling; Multi-Institutional Clinical Trial; National Clinical Trials Network; National Surgical Adjuvant Breast and Bowel Project; Operative Surgical Procedures; Outcomes Research; Pathway interactions; Patient Care; Patient-Focused Outcomes; Patients; Phase; Phase II/III Trial; Primary Brain Neoplasms; Process; Protocols documentation; Radiation Oncology; Radiation Therapy Oncology Group; Randomized; Recording of previous events; Regulation; Research; Resources; Risk; Stratification; Systemic Therapy; Technology; Testing; Therapeutic; Therapeutic Human Experimentation; Therapeutics Committee; Translational Research; Urogenital Cancer; Vision; base; biobank; cancer prevention; clinical decision-making; data management; design; improved; innovation; knowledge base; malignant breast neoplasm; novel; oncology; operation; phase III trial; programs; public health relevance; success; tumor

DESCRIPTION (provided by applicant): NRG Oncology is a newly constituted NCI National Clinical Trials Network (NCTN) network group created through the coordinated efforts of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG) with a primary vision of improving the lives of adult patients with localized or locally advanced malignancies through the conduct of high quality NCI-supported multi-institutional clinical trials. NRG Oncology (or NRG) has leveraged the tremendous resources, leadership, membership, and history of practice-defining research of the three legacy groups to create a modern clinical and translational research organization with the capability to execute clinical and translational research trials for adult patients with common and rare malignancies in the following disease sites: Gynecologic Cancer (including Ovarian, Cervix and Endometrial Cancer); Brain Tumors (Primary and Secondary); Breast Cancer; Gastrointestinal Cancers (Colorectal and Non-Colorectal Cancers); Genitourinary Cancer; Head and Neck Cancer; and Lung Cancer. NRG will be the leading network group defining new standards of care and scientific paradigms for several of these disease sites. For these seven cancer disease sites, NRG will primarily conduct trials for patients with early or intermediate stage cancers testing innovative diagnostic and therapeutic approaches, including novel imaging, radiation oncology, and surgical approaches; the integration of novel systemic agents or classes of systemic agents with optimized loco-regional therapies and existing systemic therapies, and the use of biomarker- and biologic pathway-defined approaches to risk stratification, investigational therapy assignment, and clinical trial decision-making. The group has seven scientific core committees and four integrated committees which provide both scientific support and generate protocols: Developmental Therapeutics (DT), Translational Science, Patient-Centered Outcomes Research, and Cancer Prevention and Control Committees. NRG's DT Committee builds on the GOG DT Committee's success in enrolling over 500 patients/year on early phase trials leading to phase III trials. The NRG Operations Center is fully aligned with NRG Oncology Statistical and Data Management Center (SDMC) and the NRG Biorepositories and will be fully compliant with all NCI regulations and proactive in improving the efficiency and quality of its research. The group will serve as a scientific resource for other NCTN network groups for radiation oncology innovation through its Center for Innovative Radiation Oncology (CIRO).

描述(由申请人提供)：NRG肿瘤学是一个新成立的NCI国家临床试验网络(NCTN)网络小组，由国家外科辅助乳肠计划(NSABP)、放射治疗肿瘤组(RTOG)和妇科肿瘤小组(GOG)协调努力创建，主要目标是通过进行高质量的NCI支持的多机构临床试验来改善患有局部或局部晚期恶性肿瘤的成年患者的生活。NRG肿瘤学(或NRG)利用三个传统组织的巨大资源、领导力、成员资格和实践定义研究的历史，创建了一个现代临床和转化性研究组织，有能力为以下疾病地点的常见和罕见恶性肿瘤的成年患者执行临床和转化性研究试验：妇科癌症(包括卵巢癌、子宫颈癌和子宫内膜癌)；脑肿瘤(原发和继发性)；乳腺癌；胃肠癌(结直肠癌和非结直肠癌)；泌尿生殖系癌；头颈部癌症；以及肺癌。NRG将成为为其中几个疾病地点确定新的护理标准和科学范例的领先网络小组。对于这七个癌症疾病地点，NRG将主要为早期或中期癌症患者进行试验，测试创新的诊断和治疗方法，包括新的成像、放射肿瘤学和手术方法；将新的系统药物或系统药物类别与优化的局部治疗和现有的系统治疗相集成，以及使用生物标记物和生物路径定义的方法进行风险分层、研究性治疗分配和临床试验决策。该小组有七个科学核心委员会和四个综合委员会，它们既提供科学支持，又制定方案：发展治疗(DT)、转化科学、以患者为中心的结果研究和癌症预防和控制委员会。NRG的DT委员会是在GOG DT委员会成功招募500多名患者参加导致第三阶段试验的早期试验的基础上发展起来的。NRG运营中心与NRG肿瘤学统计和数据管理中心(SDMC)以及NRG生物库完全一致，将完全遵守NCI的所有规定，并积极提高其研究的效率和质量。该小组将通过其创新放射肿瘤学中心(CERO)为其他NCTN网络小组提供放射肿瘤学创新的科学资源。